Lunit (328130) Fundamentals 2026 — Revenue Analysis | SniperIQ
Lunit (328130) is a KR-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of ₩537.4B, trading at ₩9200.00 on the KOE. This SniperIQ fundamentals page covers Lunit's valuation, profitability (net margin -75.5%), revenue (₩83.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Lunit's market cap?
Lunit (328130) has a market capitalization of approximately ₩537.4B, trading at ₩9200.00 on the KOE. Market cap moves with the live share price.
What is Lunit's P/E ratio?
Lunit's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Lunit?
Lunit runs a net profit margin of -75.5%, a gross margin of 42.4%, and an operating margin of -86.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Lunit generate?
Lunit reported revenue of ₩83.1B for fiscal year 2025, with net income of -₩46.6B and earnings per share (EPS) of -798.81. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Lunit pay a dividend?
Lunit does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Lunit financially healthy?
Lunit carries a debt-to-equity ratio of 1.19x and a current ratio of 0.32x, with a market beta of 1.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Lunit a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Lunit (328130) the key facts are: market cap ₩537.4B, revenue ₩83.1B, 52-week range 9090-24550. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Lunit's full fundamentals live
Get Lunit's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.